Mark Zuckerberg and wife Dr. Priscilla Chan recently announced a $3 billion initiative geared towards curing most of the world’s diseases called the Biohub. Through the Chan Zuckerberg Initiative, the couple managed to draw support from other billionaires and ordinary people alike in terms of funding and cooperation. Recently, the Facebook founder released a post detailing how a meeting with top scientists gave him hope that most, if not all of the world’s diseases will be gone by 2115.
The scientists in question are at the top of their fields with regards to dealing with illnesses and they come from multiple origins, including Stanford University and UC Berkeley. Heading the team is Dr. Cori Bargmann, who is a Rockefeller neuroscientist, Futurism reports.
Even with excellent brains behind the operation, the goal of eradicating even just a majority of the known diseases plaguing the world is a monumental undertaking. Much of the challenges has to do with research, which is a costly and time-consuming affair. The Biohub will take on a lot of the weight of the problems that usually prevent scientists from making swift progress, but even then, many would consider the 100-year timeline to be overly ambitious.
Zuckerberg and the team of scientists don’t seem to think so, however, and they point to the advancements that humanity has achieved in the last few decades in extending human lifespan. Global Futurist also notes how the initiative has already addressed one of the hurdles of getting to the point that they are aiming for; coordination.
There’s also the matter of the most recent innovations in medical and bioresearch to consider, which gives the lofty goals of a disease-free world a boost. There’s the new gene-editing tool called CRISPR, which is basically a starter kit for playing God. Then there’s the project called Cell Atlas, which aims to map all of the human body’s cells to address diseases that begin at the cellular level.


Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



